StockpollyBeta
Get App
Popularity #824
TEVA · NYSE · Drug Manufacturers - Specialty & Generic

Teva (ADR) (TEVA)

Combines global generics scale with innovative neuroscience and immunology medicines.

$39.38
vs last close−0.14 (−0.35%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue3,8504,4573,8194,1644,3314,2293,8914,1764,4804,7113,9814,142
Cost of revenue1,9992,0412,0482,1402,1832,1092,0142,0742,1762,0562,0111,989
Gross profit1,8512,4161,7712,0242,1482,1201,8772,1022,3042,6561,9722,153
1,5071,6601,9892,0292,1992,1491,3581,6471,4222,3551,3182,004
Research & development253234242269240271247244256267222250
8449028869399249529199599731,1201,0001,034
Selling & marketing576610608656626650622654656753696717
General & administrative268292278283298302297305317367304317
Other expenses4105248618211,03592619244419396896720
Operating income344756−218−5−51−29519455882300652149
−280−248−253−239−270−218−225−251−234−209−216−604
Interest expense280260250241272−763225203209292201200
Other non-operating income0−495−181−922−1904927−7214409
Income before tax64508−471−244−321−24729420464891436−455
Income tax expense−1241−52630692874−78214−39067121
Net income from continuing operations76467−419−874−390−275220282434481369−576
Other adjustments100−100000−100
Net income69463−139−846−437−217214282433480369−576
EPS, basic$0.07$0.41−$0.13−$0.74−$0.39−$0.19$0.19$0.25$0.38$0.42$0.32−$0.49
EPS, diluted$0.07$0.41−$0.13−$0.74−$0.39−$0.19$0.18$0.24$0.37$0.41$0.31−$0.49
Weighted average shares, basic1,1211,1211,1231,1331,1331,1331,1381,1471,1471,1491,1561,165
Weighted average shares, diluted1,1351,1371,1231,1331,1331,1331,1591,1611,1641,1731,1791,181
EBITDA6271,517552462071,1629536571,104632877−19
Depreciation & amortization283266272259259269244251249260239241
EBIT3441,251−217−13−52893709406855372638−260